VITAFLUX: Water Soluble Vitamins and Trace Elements Loss in Hemodiafiltration Patients

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Completed
CT.gov ID
NCT05099185
Collaborator
(none)
39
1
4.7
8.2

Study Details

Study Description

Brief Summary

End stage renal disease is a severe pathology in which some toxic waste and an excessive amount of water can accumulate in the human body with life threatening consequences. Maintenance hemodialysis is one of the possible treatment for this disease.

Hemodialysis filter the blood through a membrane according to a dialysis bath and so can be able to purify the blood of the toxic waste.

Otherwise, since the 1980s, the investigator know that patient in maintenance hemodialysis can have some deficiency in water soluble vitamins and trace elements. Mechanisms of the deficiency are multiple (a decreased of food intake, a diminution of the appetite, digestive malabsorption du to medics and comorbidities and loss in hemodialysis).

Impact of this deficiency have an important impact on vital prognosis for these patients. These nutrients are essential for AND synthesis, mechanism of inflammation, cells membranes synthesis, etc. DOPPs study in 2004 have shown a decreased of 16% in the mortality within 4 years with supplemented patients. Also, since this study, international recommendations were wrote in 2009, then in 2020, in order to supplement in vitamins and trace elements patients in maintenance conventional hemodialysis.

Despite these recommendations, some supplementary efforts are necessary, especially since online hemodiafiltration, a new process, is widely available and used in particular in Europe. This process combines 2 phenomena, diffusion and convection, through high-flux membranes. This process can remove a large quantity of molecule present in blood and especially the middle-molecule. In return, a more important quantity of water soluble vitamins and oligo-elements could be removed by this technique.

Also, the investigator would like to measure this loss of vitamins and trace-elements in patients with maintenance online post-dilution hemodiafiltration process with dialysate sample and blood concentrations measured (usual patient monitoring) during the session.

Condition or Disease Intervention/Treatment Phase
  • Biological: Water-soluble vitamins and trace elements measures

Study Design

Study Type:
Observational
Actual Enrollment :
39 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Measurement of Water-soluble Vitamins and Trace Elements Loss With Maintenance Post-dilution Haemodiafiltration Patient
Actual Study Start Date :
Jul 19, 2021
Actual Primary Completion Date :
Dec 10, 2021
Actual Study Completion Date :
Dec 10, 2021

Arms and Interventions

Arm Intervention/Treatment
Maintenance online post-dilution hemodiafiltration patients

Maintenance hemodialysis patients who undergo hemodialysis 3 times per week with online post-dilution hemodiafiltration process

Biological: Water-soluble vitamins and trace elements measures
We would like to measure water-soluble vitamins (B1, B6, B9, B12, C) and trace elements (zinc, selenium) in blood and dialysate for the patients treated by online post-dilution hemodiafiltration patients. There measures on blood are done systematically during the half-yearly report of our patients in our hemodialysis center. Only results are collect for the study.

Outcome Measures

Primary Outcome Measures

  1. Comparison of the blood concentrations measured in vitamins and trace elements before and after the hemodialysis session by the post-dilution HDF technique during the half-yearly assessment (usual patient follow-up). [Day 1]

    We would like to measure the concentrations of water-soluble vitamins and trace elements in dialysate by collecting 1% of this by Theraflux® device, and compare to the blood concentration collecting during the half-yearly report at the beginning then at the end of one hemodialysis session with online post-dilution hemodiafiltration session.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 130 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Maintenance hemodialysis more than 3 months

  • 3 sessions per week during 4 hours

  • Hemodiafiltration process used with this patient on Lyon Sud Hospital

  • Flow of the vascular access > 300 mL/min at least

  • Age > 18 years

  • Patient able to understand the study's goal

Exclusion Criteria:
  • Active infectious or inflammatory disease

  • Active malignant disease

  • Intestinal malabsorptive disease

  • Polysulfone's dialysis membrane allergy

  • Patient under guardianship and judicial protection

  • Pregnant and breastfeeding woman

  • Opposition to the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier Lyon Sud Pierre-Bénite France 69310

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

  • Principal Investigator: Etienne NOVEL-CATIN, MD, Nephrology department

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT05099185
Other Study ID Numbers:
  • 69HCL21_0491
  • 2021-A01241-40
First Posted:
Oct 29, 2021
Last Update Posted:
May 5, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 5, 2022